Background Emerging evidence shows that α-synuclein seed amplification assays (SAAs)
have the potential to differentiate people with Parkinson's disease from healthy controls. We …

Alpha-synuclein seed amplification assays (αSyn-SAAs) are promising diagnostic tools for
Parkinson’s disease (PD) and related synucleinopathies. They enable detection of seeding-…

Importance There is a critical need for careful and independent validation of reported
symptomatic efficacy and dopaminergic biomarker changes induced by nilotinib in Parkinson …

Eight manufacturing facilities participating in the National Institutes of Health–sponsored
Clinical Islet Transplantation (CIT) Consortium jointly developed and implemented a …

Background and Objectives The University of Pennsylvania Smell Identification Test (UPSIT)
is commonly used to assess olfaction and screen for early detection of disorders including …

Background: Investigation of sex-related motor and non-motor differences and biological
markers in Parkinson’s disease (PD) may improve precision medicine approach. Objective: To …

Introduction We sought to examine whether levels of soluble alpha-synuclein (α‐syn),
amyloid-beta (Aβ42), phosphorylated tau (p-tau), and total tau (t-tau), as measured in …

Yellow KK mice carrying the 'yellow obese' gene A y are a well established polygenic model
for human non–insulin dependent diabetes mellitus. These animals develop marked …

Background Recent research demonstrates that α-synuclein seed amplification assays (αSyn-SAA)
accurately differentiate Parkinson’s disease (PD) patients from healthy controls (HC). …

Background Nilotinib, a tyrosine kinase Abelson inhibitor, exhibits neuroprotective effects in
preclinical Parkinson disease (PD) models. Methods This Phase 2A double-blind placebo-…